Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 988 | 83 | 896 |
| Samples | 291 | 47 | 242 |
| Peptides | 268 | 35 | 237 |
Function
FIP1L1 · Factor interacting with PAPOLA and CPSF1
This gene encodes a subunit of the CPSF (cleavage and polyadenylation specificity factor) complex that polyadenylates the 3' end of mRNA precursors. This gene, the homolog of yeast Fip1 (factor interacting with PAP), binds to U-rich sequences of pre-mRNA and stimulates poly(A) polymerase activity. Its N-terminus contains a PAP-binding site and its C-terminus an RNA-binding domain. An interstitial chromosomal deletion on 4q12 creates an in-frame fusion of human genes FIP1L1 and PDGFRA (platelet-derived growth factor receptor, alpha). The FIP1L1-PDGFRA fusion gene encodes a constitutively activated tyrosine kinase that joins the first 233 amino acids of FIP1L1 to the last 523 amino acids of PDGFRA. This gene fusion and chromosomal deletion is the cause of some forms of idiopathic hypereosinophilic syndrome (HES). This syndrome, recently reclassified as chronic eosinophilic leukemia (CEL), is responsive to treatment with tyrosine kinase inhibitors. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 226 amino-acid changes on canonical ENST00000337488 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FIP1L1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FIP1L1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| Endometrial Carcinoma | 3/42 7% | 15/612 2% |
| Plasma Cell Myeloma | 4/44 9% | 2/305 1% |
| Melanoma | 5/210 2% | 28/1899 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 18/1390 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 10/810 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Colorectal Carcinoma | 7/143 5% | 25/3239 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Bladder Carcinoma | 0/58 0% | 8/956 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 18/2550 1% |
| Non-Cancerous | 2/104 2% | 5/830 1% |
| Other Solid Cancers | 1/94 1% | 11/1515 1% |
| Gastric Carcinoma | 2/74 3% | 12/1809 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Hepatocellular Carcinoma | 4/46 9% | 9/2210 0% |
| Head and Neck Carcinoma | 1/85 1% | 8/1574 1% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Breast Carcinoma | 2/144 1% | 14/3264 0% |
| Prostate Carcinoma | 0/13 0% | 10/2105 0% |
| Ovarian Carcinoma | 0/109 0% | 5/998 0% |
| Mesothelioma | 0/62 0% | 1/165 1% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 6/1592 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 8/2534 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Other Sarcomas | 2/69 3% | 0/699 0% |
| Pancreatic Carcinoma | 0/89 0% | 4/1611 0% |
Mutation Distribution
Where FIP1L1 is mutated · all tissues, split by cell line vs tissue
How many mutations in FIP1L1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 988 mutations in FIP1L1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|